4.7 Article

Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study

期刊

EUROPEAN JOURNAL OF NEUROLOGY
卷 29, 期 2, 页码 400-412

出版社

WILEY
DOI: 10.1111/ene.15138

关键词

brain dysfunction; cognitive impairment; HCV; hepatic encephalopathy; liver cirrhosis

资金

  1. Carlos III Institute of Health
  2. Rio-Hortega Research Fellowship from the Health Research Fund (Carlos III Institute of Health) [CM14/0023]
  3. Ramon y Cajal Research Fellowship [RYC-2017-23144]
  4. Spanish Ministry of Science, Innovation, and Universities
  5. NARSAD independent investigator grant from the Brain & Behavior Research Foundation [24628]
  6. Carlos III Institute of Health - ERDF Funds from the European Commission, A Way of Making Europe [PI15/00723, PI18/00753, PI21/00701]
  7. CIBERSAM
  8. Madrid Regional Government [B2017/BMD-3740 AGES-CM-2]
  9. European Union Structural Funds
  10. European Union Seventh Framework Program
  11. European Union H2020 Program
  12. Alonso Family Foundation
  13. Alicia Koplowitz Foundation
  14. Health Research Fund (Carlos III Institute of Health) [JR14/00019]
  15. [GLD15/00226]

向作者/读者索取更多资源

Hepatitis C virus (HCV) infection is associated with neuropsychiatric disturbances that impact functioning and health-related quality of life. This study found that eradication of HCV can decrease cognitive impairment prevalence and improve functioning and HRQoL, with older patients and those with baseline cognitive impairment benefitting the most. Persistent cognitive impairment may be associated with factors like higher cardiovascular risk, cirrhosis, lower education, and higher anxiety and depression scores.
Background and purpose Hepatitis C virus (HCV) infection is associated with neuropsychiatric disturbances that impact on functioning and health-related quality of life (HRQoL). Reversibility at different liver disease stages is unknown, particularly in cirrhosis. We aimed to evaluate cognition, functioning, and HRQoL following HCV eradication at different liver disease stages. Methods A random sample (n = 152) of consecutive patients treated with direct-acting antiviral agents (DAAs) between April 2015 and March 2017 were included. A comprehensive neuropsychological assessment, functioning and HRQoL questionnaires were applied at baseline, and 12 and 48 weeks after the end of antivirals. Results One-hundred thirty-five patients who achieved virological response completed the follow-up, of whom 44 had cirrhosis (27% decompensated). Twenty-one percent had cognitive impairment before starting DAAs (34.1% cirrhotic vs. 14.4% noncirrhotic, p < 0.011). Viral eradication was associated with a decrease in cognitive impairment to 23% of cirrhotic and 6% of noncirrhotic patients (p < 0.05). Interestingly, older patients (B = 0.11, 95% confidence interval [CI] = 0.03-0.19) with baseline cognitive impairment (B = 3.58, 95% CI = 1.54-5.62) were those with higher cognitive benefit, regardless of liver disease. Persistent cognitive impairment was associated with having higher cardiovascular risk, cirrhosis, lower education, and higher anxiety and depression scores. Functioning and HRQoL also improved after eradication but remained worse in the cirrhotic group. Conclusions Viral eradication decreases the prevalence of cognitive impairment and improves functioning and HRQoL. Patients with lower brain reserve (older patients) and baseline cognitive impairment may benefit the most. Identification and treatment of HCV patients through screening programs may reduce the burden of cognitive disturbances beyond the prevention of liver disease progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据